We are building
a hyper scalable biotech
Vial was founded on a mission to reimagine drug development by building for hyper scale.
Meet Our Team
Samir Meghji Chief Financial Officer
Anita Ebeye Clinical Trial Lead
Jun-Goo Kwak Strategy Associate
Our Investors
We have raised $100M+ to reimagine drug development.
Scientific Advisory Board
Vial CRO is supported by a team of Scientific Advisors who review and provide input on the strategy and direction of our program development.
Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School
Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah
More than 10 years as a Vitreo-Retinal Physician and Surgeon, as well as Director of Clinical Research at his practice, Sierra Eye Associates
Director of Summit Cancer Centers, Medical Oncologist
Director of the Center for Innovation in Brain Science at The University of Arizona and founder of NeuTherapeutics
Senior physician of Pariser Dermatology Specialist and Principal Investigator
VP, Early Stage Development at
Seagen
Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles
Associate Professor in the Department of Dermatology and Department of Medicine, Division of Rheumatology at Harvard Medical School
Director of Retina Services at the Pepose Vision Institute
VP, Early Stage Development at
Seagen
Dr. Egilius L.H. Spierings
Founder, Medical Director, and Investigator at MedVadis Research Corporation
Dr. Rajat Agrawal
VP of Clinical Development and Ophthalmology Lead at Rezolute, Inc. and the founder, president, and CEO of an international nonprofit, Retina Global
Dr. Stewart Tepper
Professor of Neurology and Neurologist at the Dartmouth-Hitchcock Medical Center
Dr. Jacqueline French
Professor of Neurology at the Comprehensive Epilepsy Center at NYU Grossman School of Medicine and the President, Director, and Founder of The Epilepsy Study Consortium.
Dr. Christopher Sweeney
Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) and Professor of Medicine at the University of Adelaide
Dr. Peter Goadsby
Director of the NIHR Wellcome Trust at the King's College Clinical Research Facility and Professor of Neurology at the University of California, San Francisco
Dr. Veeral Sheth
Director of Clinical Research at the University Retina and Macula Associates and a Clinical Assistant Professor at the University of Illinois
Professor at the Medical College of Wisconsin and the Founder, Owner, and CEO of Diverge Translational Science Laboratory
Professor and Chair of Dermatology, Residency Program Director of Translational Research, and Director of Supportive Oncodermatology at George Washington University
Medical Director for Lean and Quality Improvement, Chair of the Lymphoma/Myeloma Disease Working Group, and Associate Professor at the University of Kansas
Chief of the Parkinson’s and Movement Disorder Division at the University of Kansas Medical Center
Professor of Neurology and Director of the Parkinson’s Disease Center and Movement Disorders Clinic at the Baylor College of Medicine
Professor of Neurology and Director of the Parkinson’s Disease Center and Movement Disorders Clinic at the Baylor College of Medicine
Clinical Executive Director at AccessHope
Genitourinary Medical Oncology Professor and Physician at The University of Texas MD Anderson Cancer Center, Houston, TX
Chief of Clinical Trials at Vanderbilt University
We are reimagining drug discovery
Powered by a computational discovery engine and automated clinical trials, our hyper scalable model is transforming drug development.
